Cabaletta Bio Inc (OQ:CABA)

Mar 21, 2024 07:00 am ET
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results...
Mar 20, 2024 07:00 am ET
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug...
Feb 27, 2024 08:00 am ET
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in...
Feb 01, 2024 04:30 pm ET
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug...
Jan 31, 2024 08:00 am ET
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief...
Jan 08, 2024 07:00 am ET
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug...
Jan 02, 2024 08:00 am ET
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief...
Nov 28, 2023 04:30 pm ET
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief...
Nov 09, 2023 07:00 am ET
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the third quarter...
Nov 06, 2023 08:15 am ET
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today anno
Nov 06, 2023 07:00 am ET
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company’s fourth...
Oct 30, 2023 08:00 am ET
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in...
Oct 02, 2023 07:00 am ET
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company’s third...
Sep 25, 2023 09:31 am ET
Thinking about buying stock in Nikola Corp, Eos Energy Enterprises, Applied Therapeutics, Tango Therapeutics, or Cabaletta Bio?
NEW YORK, Sept. 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKLA, EOSE, APLT, TNGX, and CABA.
Sep 19, 2023 08:00 am ET
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in...
Aug 30, 2023 08:00 am ET
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in...
Aug 22, 2023 08:00 am ET
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that it has entered into certain work...
Aug 10, 2023 07:00 am ET
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the second quarter...
Jul 24, 2023 08:00 am ET
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the appointment of Shawn Tomasello to...
Jun 20, 2023 08:00 am ET
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors
Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to...
May 31, 2023 08:00 am ET
Cabaletta Bio to Present at the Jefferies Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief...
May 23, 2023 11:29 am ET
Thinking about buying stock in Cabaletta, Core Molding, BioVie, Tidewater, or Paysign?
NEW YORK, May 23, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CABA, CMT, BIVI, TDW, and PAYS.
May 22, 2023 04:30 pm ET
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, announced today the...
May 17, 2023 10:16 pm ET
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the...
May 17, 2023 04:01 pm ET
Cabaletta Bio Announces Proposed Public Offering of Common Stock
Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, announced today that it...
May 16, 2023 11:45 am ET
Thinking about buying stock in Cabaletta Bio, SNDL, Roblox, DraftKings, or Riot Platforms?
NEW YORK, May 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CABA, SNDL, RBLX, DKNG, and RIOT.
May 16, 2023 11:45 am ET
Thinking about buying stock in Nu Holdings, Cabaletta Bio, CVRx, Alphatec Holdings, or TransMedics?
NEW YORK, May 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NU, CABA, CVRX, ATEC, and TMDX.
May 16, 2023 07:00 am ET
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company’s second...
May 11, 2023 07:00 am ET
Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the first quarter...
May 02, 2023 04:35 pm ET
Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Samik Basu, M.D., Chief Scientific...
May 01, 2023 07:00 am ET
Cabaletta Bio Receives FDA Fast Track Designation for CABA-201
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug...
Apr 25, 2023 08:00 am ET
Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief...
Apr 13, 2023 04:30 pm ET
Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief...
Mar 31, 2023 07:00 am ET
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company’s Investigational New...
Mar 16, 2023 07:00 am ET
Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the fourth quarter...
Feb 28, 2023 08:00 am ET
Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief...
Jan 09, 2023 07:00 am ET
Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc (Nasdaq:...
Jan 05, 2023 08:00 am ET
Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief...
Dec 08, 2022 07:00 am ET
Cabaletta Bio Announces $35 Million Offering
Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that it...
Nov 22, 2022 08:00 am ET
Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
Nov 10, 2022 07:00 am ET
Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the third quarter...
Oct 19, 2022 08:30 am ET
Thinking about buying stock in Momentive Global, Agrify, Cabaletta Bio, United Airlines, or Kaival Brands?
NEW YORK, Oct. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNTV, AGFY, CABA, UAL, and KAVL.
Oct 11, 2022 07:00 am ET
Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced CABA-201, a newly designed, fully human...
Oct 06, 2022 08:00 am ET
Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present clinical and translational...
Sep 26, 2022 08:00 am ET
Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief...
Sep 10, 2022 07:00 am ET
Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational data through 6...
Sep 06, 2022 08:00 am ET
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming...
Aug 29, 2022 01:58 pm ET
Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present new clinical and...
Aug 11, 2022 07:00 am ET
Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today reported financial results for the second quarter ended June...
May 18, 2022 07:00 am ET
Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational data through 6...
May 17, 2022 08:00 am ET
Cabaletta Bio to Present at the H.C. Wainwright Global Investment Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief...
May 12, 2022 07:00 am ET
Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today reported financial results for the first quarter ended...
May 09, 2022 11:54 am ET
Lifshitz Law PLLC. Announces Investigations of Affirm Holdings, Inc. (NASDAQ: AFRM), C3.ai, Inc. (NYSE: AI), Cabaletta Bio, Inc. (NASDAQ: CABA), and Rivian Automotive (NASDAQ: RIVN)
Affirm Holdings, Inc. (NASDAQ: AFRM) Lifshitz Law PLLC announces that a class action complaint was filed against Affirm alleging that Affirm made materially false and/or misleading statements and/or failed to disclose that: (i) Affirm's "buy...
May 02, 2022 04:30 pm ET
Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that data from its two lead programs, DSG3-CAART...
Apr 29, 2022 01:09 pm ET
CABA FINAL DEADLINE TODAY: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important April 29 Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public...
Apr 29, 2022 11:11 am ET
CABA FINAL DEADLINE TODAY: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important April 29 Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public...
Apr 29, 2022 10:00 am ET
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, April 29, 2022 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cabaletta Bio, Inc. ("Cabaletta" or "the Company") (NASDAQ: CABA) for violations of the federal securities laws.
Apr 29, 2022 05:45 am ET
CABA SHAREHOLDER ALERT: Jakubowitz Law Reminds Cabaletta Shareholders of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, April 29, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA).
Apr 28, 2022 12:31 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline – CABA
Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta or the “Company”) (NASDAQ: CABA) and certain of its officers.   The class action, filed in the United States District Court for the Eastern...
Apr 28, 2022 05:45 am ET
CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 28, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsuit.
Apr 27, 2022 09:00 pm ET
CABALETTA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Cabaletta Bio, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (NASDAQ: CABA) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired Cabaletta securities between October 24, 2019 and December 13, 2021, both dates included (the “Class Period”); or who purchased or otherwise acquired Cabaletta common stock pursuant and/or traceable to the October 24, 2019 IPO. Inve
Apr 27, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cabaletta Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 29, 2022 - (NASDAQ: CABA)
NEW YORK, April 27, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cabaletta Bio, Inc..
Apr 26, 2022 05:45 am ET
CABA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 29, 2022 in the Class Action Filed on Behalf of Cabaletta Bio, Inc. Shareholders
NEW YORK, April 26, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA) alleging that the Company violated federal securities laws.
Apr 25, 2022 11:00 am ET
Bronstein, Gewirtz & Grossman, LLC Reminds Cabaletta Bio, Inc. (CABA) Investors of Class Action Deadline and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta" or "the Company") (NASDAQ: CABA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to the prospectus which incorporated and formed part of the registration statement (the "Prospectus" and, together with the Registration Statement, the "Offering Documents") issued in connection with the Company's initial public offering conducted on or about Oc
Apr 25, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Cabaletta Investors of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, April 25, 2022 /PRNewswire/ -- Attention Cabaletta Bio, Inc. ("Cabaletta") (NASDAQ: CABA) shareholders:
Apr 24, 2022 05:00 pm ET
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important April 29 Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public...
Apr 22, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Affirm, Cabaletta, Ericsson, and C3.ai and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Affirm Holdings, Inc. (NASDAQ: AFRM), Cabaletta Bio, Inc. (NASDAQ: CABA),...
Apr 21, 2022 05:45 am ET
CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 21, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsuit.
Apr 20, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cabaletta Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 29, 2022 - (NASDAQ: CABA)
NEW YORK, April 20, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cabaletta Bio, Inc..
Apr 19, 2022 05:15 pm ET
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important April 29 Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public...
Apr 19, 2022 05:45 am ET
CABA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 29, 2022 in the Class Action Filed on Behalf of Cabaletta Bio, Inc. Shareholders
NEW YORK, April 19, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA) alleging that the Company violated federal securities laws.
Apr 18, 2022 08:05 pm ET
CABA INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important April 29 Deadline in Securities Class Action - CABA
NEW YORK, April 18, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019 (the "IPO" or "Offering"); and/or (ii) between October 24, 2019 and December 13, 2021, both dates inclusive (the "Class Period"), of the important April 29, 2022 lead plaintiff deadline.
Apr 18, 2022 09:22 am ET
CABA 11-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Cabaletta Bio (CABA) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pendin
Hagens Berman urges Cabaletta Bio, Inc. (NASDAQ: CABA) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: Oct. 21, 2019...
Apr 18, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Cabaletta Investors of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, April 18, 2022 /PRNewswire/ -- Attention Cabaletta Bio, Inc. ("Cabaletta") (NASDAQ: CABA) shareholders:
Apr 17, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Affirm, Cabaletta, Ericsson, and C3.ai and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Affirm Holdings, Inc. (NASDAQ: AFRM), Cabaletta Bio, Inc. (NASDAQ: CABA),...
Apr 15, 2022 05:45 am ET
CABA SHAREHOLDER ALERT: Jakubowitz Law Reminds Cabaletta Shareholders of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, April 15, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA).
Apr 14, 2022 12:20 pm ET
GATO, CRNC & CABA: Bronstein, Gewirtz & Grossman, LLC, A Top Class Action Firm, Reminds Investors of Upcoming Deadlines and Encourages Investors to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 14, 2022 05:45 am ET
CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsuit.
Apr 13, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cabaletta Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 29, 2022 - (NASDAQ: CABA)
NEW YORK, April 13, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cabaletta Bio, Inc..
Apr 12, 2022 06:00 pm ET
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cabaletta Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public...
Apr 12, 2022 05:45 am ET
CABA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 29, 2022 in the Class Action Filed on Behalf of Cabaletta Bio, Inc. Shareholders
NEW YORK, April 12, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA) alleging that the Company violated federal securities laws.
Apr 11, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cerence, Affirm, Cabaletta, and Ericsson and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Cerence, Inc. (NASDAQ: CRNC), Affirm Holdings, Inc. (NASDAQ: AFRM), Cabaletta...
Apr 11, 2022 06:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline - CABA
NEW YORK, April 11, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta or the "Company") (NASDAQ: CABA) and certain of its officers.   The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 22-cv-00737, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Comp
Apr 11, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Cabaletta Investors of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, April 11, 2022 /PRNewswire/ -- Attention Cabaletta Bio, Inc. ("Cabaletta") (NASDAQ: CABA) shareholders:
Apr 08, 2022 05:45 am ET
CABA SHAREHOLDER ALERT: Jakubowitz Law Reminds Cabaletta Shareholders of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, April 8, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA).
Apr 07, 2022 12:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline – CABA
Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta or the “Company”) (NASDAQ: CABA) and certain of its officers. The class action, filed in the United States District Court for the Eastern...
Apr 07, 2022 05:45 am ET
CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors Of A Class Action Lawsuit And Upcoming Deadline
NEW YORK, April 7, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsuit.
Apr 06, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cabaletta, Ericsson, C3.ai, and Rivian and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Cabaletta Bio, Inc. (NASDAQ: CABA), Telefonaktiebolaget LM Ericsson (NASDAQ:...
Apr 06, 2022 11:13 am ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public...
Apr 06, 2022 08:00 am ET
Cabaletta Bio to Present at the 21st Annual Needham Virtual Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Gwendolyn Binder, Ph.D., President of Science...
Apr 06, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cabaletta Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 29, 2022 - (NASDAQ: CABA)
NEW YORK, April 6, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cabaletta Bio, Inc..
Apr 05, 2022 05:45 am ET
CABA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 29, 2022 in the Class Action Filed on Behalf of Cabaletta Bio, Inc. Shareholders
NEW YORK, April 5, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA) alleging that the Company violated federal securities laws.
Apr 04, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Cabaletta Investors of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, April 4, 2022 /PRNewswire/ -- Attention Cabaletta Bio, Inc. ("Cabaletta") (NASDAQ: CABA) shareholders:
Apr 03, 2022 03:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline - CABA
NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta or the "Company") (NASDAQ: CABA) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 22-cv-00737, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company
Apr 01, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Affirm, Cabaletta, Ericsson, and C3.ai and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Affirm Holdings, Inc. (NASDAQ: AFRM), Cabaletta Bio, Inc. (NASDAQ: CABA),...
Apr 01, 2022 05:45 am ET
CABA SHAREHOLDER ALERT: Jakubowitz Law Reminds Cabaletta Shareholders of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, April 1, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA).
Mar 31, 2022 05:45 am ET
CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 31, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsuit.
Mar 30, 2022 07:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline – CABA
Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta or the “Company”) (NASDAQ: CABA) and certain of its officers.   The class action, filed in the United States District Court for the Eastern...
Mar 30, 2022 05:30 pm ET
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cabaletta Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public offering conducted on or about October 24, 2019 (the “IPO” or “Offering”); and/or (ii) between October 24, 2019 and December 13, 2021, both dates inclusive (the “Class Period”), of the important April 29, 2022 lead plaintiff deadline.
Mar 30, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cabaletta Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 29, 2022 - (NASDAQ: CABA)
NEW YORK, March 30, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cabaletta Bio, Inc..
Mar 29, 2022 12:10 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Cabaletta Bio, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public...
Mar 29, 2022 05:45 am ET
CABA ALERT: The Klein Law Firm Announces A Lead Plaintiff Deadline Of April 29, 2022 In The Class Action Filed On Behalf Of Cabaletta Bio, Inc. Shareholders
NEW YORK, March 29, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA) alleging that the Company violated federal securities laws.
Mar 28, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Cabaletta Investors of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, March 28, 2022 /PRNewswire/ -- Attention Cabaletta Bio, Inc. ("Cabaletta") (NASDAQ: CABA) shareholders:
Mar 27, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Affirm, Cabaletta, Ericsson, and C3.ai and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Affirm Holdings, Inc. (NASDAQ: AFRM), Cabaletta Bio, Inc. (NASDAQ: CABA),...
Mar 26, 2022 01:30 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline - CABA
NEW YORK, March 26, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta or the "Company") (NASDAQ: CABA) and certain of its officers.  The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 22-cv-00737, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compa
Mar 25, 2022 05:45 am ET
CABA SHAREHOLDER ALERT: Jakubowitz Law Reminds Cabaletta Shareholders of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, March 25, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA).
Mar 24, 2022 05:45 am ET
CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 24, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsuit.
Mar 23, 2022 04:00 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Cabaletta Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public...
Mar 23, 2022 06:00 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cabaletta Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 29, 2022 - (NASDAQ: CABA)
NEW YORK, March 23, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cabaletta Bio, Inc.
Mar 22, 2022 06:00 am ET
CABA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 29, 2022 in the Class Action Filed on Behalf of Cabaletta Bio, Inc. Shareholders
NEW YORK, March 22, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA) alleging that the Company violated federal securities laws.
Mar 21, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Affirm, Cabaletta, Ericsson, and C3.ai and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Affirm Holdings, Inc. (NASDAQ: AFRM), Cabaletta Bio, Inc. (NASDAQ: CABA),...
Mar 21, 2022 06:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline – CABA
Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta" or the “Company”) (NASDAQ: CABA) and certain of its officers. The class action, filed in the United States District Court for the Eastern...
Mar 21, 2022 06:00 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Cabaletta Investors of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, March 21, 2022 /PRNewswire/ -- Attention Cabaletta Bio, Inc. ("Cabaletta") (NASDAQ: CABA) shareholders:
Mar 18, 2022 05:04 pm ET
CABA Stock Investigation: Robbins LLP Investigates Cabaletta Bio, Inc. (CABA) on Behalf of Shareholders
Shareholder rights law firm Robbins LLP is investigating Cabaletta Bio, Inc. (NASDAQ: CABA) and its officers and directors to determine if they breached their fiduciary duties and violated securities laws in connection with the Company's initial public offering ("IPO"). Cabaletta Bio is a clinical-stage biotechnology company that dis
Mar 18, 2022 06:00 am ET
CABA SHAREHOLDER ALERT: Jakubowitz Law Reminds Cabaletta Shareholders of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, March 18, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA).
Mar 17, 2022 08:30 pm ET
CABA NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public...
Mar 17, 2022 07:00 am ET
Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today reported financial results for the fourth quarter and full...
Mar 17, 2022 06:00 am ET
CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 17, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsuit.
Mar 16, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cerence, Affirm, Cabaletta, and Ericsson and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Cerence, Inc. (NASDAQ: CRNC), Affirm Holdings, Inc. (NASDAQ: AFRM), Cabaletta...
Mar 16, 2022 08:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline - CABA
NEW YORK, March 16, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta or the "Company") (NASDAQ: CABA) and certain of its officers.  The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 22-cv-00737, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compa
Mar 16, 2022 06:00 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cabaletta Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 29, 2022 - (NASDAQ: CABA)
NEW YORK, March 16, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cabaletta Bio, Inc..
Mar 15, 2022 08:10 am ET
Investor Notice: April 29th Deadline in Lawsuit for Investors who Lost over $50,000 in Cabaletta Bio, Inc. shares announced by Shareholders Foundation
SAN DIEGO, March 15, 2022 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a deadline is coming up on April 29th, 2022, in the lawsuit that was filed for certain investors in NASDAQ: CABA shares.
Mar 15, 2022 06:00 am ET
CABA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 29, 2022 in the Class Action Filed on Behalf of Cabaletta Bio, Inc. Shareholders
NEW YORK, March 15, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA) alleging that the Company violated federal securities laws.
Mar 14, 2022 06:00 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Cabaletta Investors of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, March 14, 2022 /PRNewswire/ -- Attention Cabaletta Bio, Inc. ("Cabaletta") (NASDAQ: CABA) shareholders:
Mar 12, 2022 08:13 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline – CABA
Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (NASDAQ: CABA) and certain of its officers.   The class action, filed in the United States District Court for the Eastern...
Mar 12, 2022 05:01 pm ET
UPCOMING DEADLINE: Cabaletta Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - CABA
SAN DIEGO, March 12, 2022 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Cabaletta Bio, Inc. (NASDAQ: CABA): (a) common stock pursuant and/or traceable to the offering documents issued in connection with Cabaletta Bio's initial public offering conducted on or about October 24, 2019 (the "IPO"); and/or (b) securities between October 24, 2019 and December 13, 2021, both dates inclusive (the "Class Period") have until April 29, 2022 to seek appointment as lead plaintiff in Patterson v. Cabaletta Bio, Inc., No. 22-cv-00737 (E.D. Pa.).  Commenced
Mar 12, 2022 04:00 pm ET
ROSEN, LEADING INVESTOR COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public...
Mar 11, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MP Materials, Cerence, Affirm, and Cabaletta and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of MP Materials Corp. (NYSE: MP), Cerence, Inc. (NASDAQ: CRNC), Affirm Holdings,...
Mar 11, 2022 05:00 am ET
CABA SHAREHOLDER ALERT: Jakubowitz Law Reminds Cabaletta Shareholders of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, March 11, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA).
Mar 10, 2022 05:00 am ET
CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 10, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsuit.
Mar 09, 2022 05:00 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cabaletta Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 29, 2022 - (NASDAQ: CABA)
NEW YORK, March 9, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice on behalf of shareholders of Cabaletta Bio, Inc..
Mar 08, 2022 09:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline - CABA
NEW YORK, March 8, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta or the "Company") (NASDAQ: CABA) and certain of its officers.  The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 22-cv-00737, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan
Mar 08, 2022 05:00 am ET
CABA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 29, 2022 in the Class Action Filed on Behalf of Cabaletta Bio, Inc. Shareholders
NEW YORK, March 8, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA) alleging that the Company violated federal securities laws.
Mar 07, 2022 08:35 pm ET
NOTICE: Cabaletta Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CABA
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Cabaletta Bio, Inc. (NASDAQ: CABA): (a) common stock pursuant and/or traceable to the offering documents issued in connection with Cabaletta Bio’s initial public offering conducted on or about October 2
Mar 07, 2022 02:54 pm ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Cabaletta Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued...
Mar 07, 2022 01:23 pm ET
CABA CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Cabaletta Bio (CABA) Investors with Significant Losses to Contact Firm’s Attorneys About Opportunity to Lead Securities Fraud Act
Hagens Berman urges Cabaletta Bio, Inc. (NASDAQ: CABA) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: Oct. 21, 2019...
Mar 07, 2022 05:00 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Cabaletta Investors of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, March 7, 2022 /PRNewswire/ -- Attention Cabaletta Bio, Inc. ("Cabaletta") (NASDAQ: CABA) shareholders:
Mar 06, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Affirm and Cabaletta and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Affirm Holdings, Inc. (NASDAQ: AFRM) and Cabaletta Bio, Inc. (NASDAQ: CABA)....
Mar 05, 2022 05:01 pm ET
DEADLINE: Cabaletta Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - CABA
SAN DIEGO, March 5, 2022 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Cabaletta Bio, Inc. (NASDAQ: CABA): (a) common stock pursuant and/or traceable to the offering documents issued in connection with Cabaletta Bio's initial public offering conducted on or about October 24, 2019 (the "IPO"); and/or (b) securities between October 24, 2019 and December 13, 2021, both dates inclusive (the "Class Period") have until April 29, 2022 to seek appointment as lead plaintiff in Patterson v. Cabaletta Bio, Inc., No. 22-cv-00737 (E.D. Pa.).  Commenced
Mar 04, 2022 10:53 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cabaletta Bio, Inc., of Class Action Lawsuit and Upcoming Deadline – CABA
Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (NASDAQ: CABA) and certain of its officers.   The class action, filed in the United States District Court for the Eastern...
Mar 04, 2022 10:22 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Cabaletta Bio, Inc. (CABA) Investors of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta" or "the Company") (NASDAQ: CABA) and certain of its officers, on behalf of...
Mar 04, 2022 05:00 am ET
CABA SHAREHOLDER ALERT: Jakubowitz Law Reminds Cabaletta Shareholders of a Lead Plaintiff Deadline of April 29, 2022
NEW YORK, March 4, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA).
Mar 03, 2022 08:31 am ET
CABA INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Cabaletta Bio (CABA) Investors with Significant Losses to Contact Firm's Attorneys, Securities Class Action Filed
SAN FRANCISCO, March 3, 2022 /PRNewswire/ -- Hagens Berman urges Cabaletta Bio, Inc. (NASDAQ: CABA) investors who suffered significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.
Mar 03, 2022 05:00 am ET
CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 3, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsuit.
Mar 02, 2022 06:00 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Cabaletta Bio, Inc. (CABA)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta Bio” or the “Company”) (NASDAQ: CABA) in the United States District Court for the Eastern District of Pennsylvania on behalf of...
Mar 02, 2022 01:15 pm ET
CABA SHAREHOLDER ALERT: Robbins LLP Reminds Investors of Class Action Against Cabaletta Bio, Inc. (CABA)
The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or acquired Cabaletta Bio, Inc. (NASDAQ: CABA) (1) common stock pursuant to the Company's October 2019 IPO or (2) securities between October 24, 2019 and December 13, 202
Mar 02, 2022 11:40 am ET
CABALETTA BIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern D
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (NASDAQ: CABA) in the United States District Court for the Eastern District...
Mar 02, 2022 10:40 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cabaletta Bio, Inc. (“Cabaletta” or “the Company”) (NASDAQ:
Mar 02, 2022 09:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Cabaletta Bio, Inc. (CABA) Investors of Class Action and Encourages Investors to Contact the Firm
NEW YORK, March 2, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta" or "the Company") (NASDAQ: CABA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to the prospectus which incorporated and formed part of the registration statement (the "Prospectus" and, together with the Registration Statement, the "Offering Documents") issued in connection with the Company's
Mar 01, 2022 09:00 pm ET
CABALETTA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cabaletta Bio, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (NASDAQ: CABA) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired Cabaletta securities between October 24, 2019 and December 13, 2021, both dates included (the “Class Period”); or who purchased or otherwise acquired Cabaletta common stock pursuant and/or traceable to the October 24, 2019 IPO. Investors ha
Mar 01, 2022 07:21 pm ET
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cabaletta Bio, Inc. (“Cabaletta” or “the Company”) (NASDAQ:
Mar 01, 2022 03:57 pm ET
SHAREHOLDER ALERT: Robbins LLP Informs Investors of Class Action Against Cabaletta Bio, Inc. (CABA)
The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of persons and entities that purchased or acquired Cabaletta Bio, Inc. (NASDAQ: CABA) (1) common stock pursuant to the Company's October 2019 IPO or (2) securities between October 24, 2019 and December 13, 202
Mar 01, 2022 01:41 pm ET
(CABA) INVESTOR DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Cabaletta Class Action
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) announces that a class action has been commenced on behalf of investors of Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA). The lawsuit is currently on behalf...
Mar 01, 2022 01:32 pm ET
ALERT: Cabaletta Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - CABA
SAN DIEGO, March 1, 2022 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Cabaletta Bio, Inc. (NASDAQ: CABA): (a) common stock pursuant and/or traceable to the offering documents issued in connection with Cabaletta Bio's initial public offering conducted on or about October 24, 2019 (the "IPO"); and/or (b) securities between October 24, 2019 and December 13, 2021, inclusive (the "Class Period") have until April 29, 2022 to seek appointment as lead plaintiff in Patterson v. Cabaletta Bio, Inc., No. 22-cv-00737 (E.D. Pa.). Commenced on February 28, 2022, the Ca
Mar 01, 2022 01:07 pm ET
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cabaletta Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CABA
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public offering conducted on or about October 24, 2019 (the “IPO” or “Offering”); and/or (ii) between October 24, 2019 and December 13, 2021, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no lat
Mar 01, 2022 08:00 am ET
U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA)...
Feb 28, 2022 10:55 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action Against Cabaletta Bio, Inc., and Certain Officers - CABA
NEW YORK, Feb. 28, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta or the "Company") (NASDAQ: CABA) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 22-cv-00737, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company
Feb 28, 2022 08:00 am ET
Cabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief...
Jan 11, 2022 08:00 am ET
Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the promotions of Gwendolyn...
Jan 10, 2022 08:00 am ET
Cabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
Jan 06, 2022 05:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cabaletta Bio, Inc. - CABA
NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 03, 2022 08:00 am ET
Cabaletta Bio to Present at the H.C. Wainwright BioConnect Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
Dec 14, 2021 07:00 am ET
Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported top-line data on biologic...
Nov 09, 2021 04:30 pm ET
Cabaletta Bio to Participate in Upcoming Investor Conferences in November
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will...
Nov 09, 2021 08:00 am ET
Cabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the appointments of Samik...
Nov 01, 2021 07:05 am ET
Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported financial results for the third...
Nov 01, 2021 07:00 am ET
Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced 28-day clinical data from the...
Oct 15, 2021 04:30 pm ET
Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Wee
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that data from in vitro...
Sep 28, 2021 08:00 am ET
Cabaletta Bio to Present at the Chardan 5th Annual Genetic Medicines Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
Sep 07, 2021 08:00 am ET
Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been...
Sep 02, 2021 08:00 am ET
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will...
Aug 18, 2021 07:00 am ET
Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced 28-day data from the second...
Aug 05, 2021 07:30 am ET
Cabaletta Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported financial results for the...
Jun 28, 2021 08:00 am ET
Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the appointment of veteran...
May 27, 2021 08:00 am ET
Cabaletta Bio to Present at the Jefferies Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
May 03, 2021 07:05 am ET
Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported financial results for the first...
May 03, 2021 07:00 am ET
Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced acute safety data from the...
Apr 07, 2021 08:00 am ET
Cabaletta Bio to Present at the 20th Annual Needham Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
Mar 16, 2021 07:30 am ET
Cabaletta Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the...
Feb 23, 2021 08:00 am ET
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will...
Jan 07, 2021 08:00 am ET
Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
Jan 04, 2021 08:00 am ET
Cabaletta Bio to Participate in Upcoming January Investor Conferences
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
Dec 08, 2020 04:30 pm ET
Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes™ Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the first patient has...
Nov 23, 2020 08:00 am ET
Cabaletta Bio to Participate in Upcoming December Investor Conferences
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
Nov 10, 2020 07:30 am ET
Cabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the...
Sep 25, 2020 08:00 am ET
Cabaletta Bio to Present at Upcoming Investor Conferences in October
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
Sep 08, 2020 08:00 am ET
Cabaletta Bio to Present at Multiple Upcoming September Investor Conferences
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participation in fireside...
Aug 25, 2020 08:00 am ET
Cabaletta Bio Announces Publication of Comprehensive Preclinical Study Results for DSG3-CAART in Pemphigus Vulgaris
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced comprehensive preclinical...
Aug 06, 2020 07:30 am ET
Cabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update 
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the...
Aug 03, 2020 08:00 am ET
Cabaletta Bio to Present at Multiple August Investor Conferences
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participation in fireside...
Jul 07, 2020 08:00 am ET
Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, and Artisan Bio, Inc., a precision cell...
May 28, 2020 08:00 am ET
Cabaletta Bio Announces Expansion of Sponsored Research Agreement with the University of Pennsylvania
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the expansion of its Sponsored...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.